GlobeNewswire

Koelis Announces ProMap® Smart Automatic Prostate Contouring Software at AUA 2026
14/05/2026
PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com ), a global leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, announced [...]
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
14/05/2026
BOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Drug Administration (FDA [...]
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
14/05/2026
—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC [...]
Legal Steroids for Beginners 2026: (Muscle Growth And Fat Loss) Crazy Bulk Launched Safest Legal Steroid Alternatives Without Side Effects In USA.
14/05/2026
Effective Steroids for Beginners that actually work, for (Bulking and Cutting) without side effects, natural anabolic steroid alternatives for muscle gain To Men And Women Read First Steroid Cycle - Before And After [...]
Agomab to Participate in Upcoming Conferences
14/05/2026
Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will [...]
EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer
14/05/2026
, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited (“Telix”) to explore joint [...]
ElevateBio Data at ASGCT 29th Annual Meeting Showcase Expanded Gene Editing Platform and Services Spanning New Modalities, AI Discovery, and LNP Delivery
14/05/2026
Data highlight advancements across ElevateBio's targeted gene insertion platform, powered by retrotransposon and machine learning-optimized recombinase approaches, and its new epigenetic editing platform Adenine base [...]
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
14/05/2026
PURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced [...]
Milestone Scientific Reports Financial Results for First Quarter 2026
14/05/2026
Operating Loss Reduced As Company Advances Toward Profitability Reaffirms Outlook for Double-Digit Revenue Growth in 2026, including Significant Growth in CompuFlo® Sales ROSELAND, N.J., May 14, 2026 (GLOBE NEWSWIRE [...]
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
14/05/2026
Bria-PROS+ is BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancer Immune stimulating components of Bria-PROS+ enhance anti-tumor responses BriaCell has completed manufacturing [...]
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
14/05/2026
Randomized Phase 2 trial evaluates off-the-shelf invariant natural killer T (iNKT) cell therapy in patients with acute lung injury and hypoxemic respiratory failure Study initiates in Lviv, Ukraine, in partnership with [...]
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
14/05/2026
HCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senescent cells BPD is a rare pediatric disease affecting underweight premature infants which [...]
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
‒ Q1 2026 Net Revenue of $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million ; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today [...]
Avicanna Reports Q1 2026 Financial Statements
14/05/2026
Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform TORONTO, [...]
Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
14/05/2026
Development of a gedatolisib formulation for subcutaneous injection is underway; first patent application submitted to the U.S. Patent and Trademark Office MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. ( [...]
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
14/05/2026
Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in [...]
Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)
14/05/2026
Third Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced [...]
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
14/05/2026
Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines [...]
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
14/05/2026
Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum